Prevalence of cervical human papillomavirus in kidney transplant recipients: A systematic review and meta-analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Prevalence of cervical human papillomavirus in kidney transplant recipients : A systematic review and meta-analysis. / Ring, Linea Landgrebe; Lindquist, Sofie; Rosthøj, Susanne; Larsen, Helle K.; Hædersdal, Merete; Sørensen, Søren S.; Kjaer, Susanne K.; Sand, Freja Lærke.
I: Preventive Medicine, Bind 182, 107927, 2024.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence of cervical human papillomavirus in kidney transplant recipients
T2 - A systematic review and meta-analysis
AU - Ring, Linea Landgrebe
AU - Lindquist, Sofie
AU - Rosthøj, Susanne
AU - Larsen, Helle K.
AU - Hædersdal, Merete
AU - Sørensen, Søren S.
AU - Kjaer, Susanne K.
AU - Sand, Freja Lærke
N1 - Publisher Copyright: © 2024 Elsevier Inc.
PY - 2024
Y1 - 2024
N2 - Objective: This systematic review and meta-analysis aims to investigate the prevalence of cervical high-risk human papillomavirus (hrHPV) among kidney transplant recipients (KTRs) and, furthermore to compare it to that in immunocompetent controls. Methods: A systematic literature search was conducted in PubMed, EMBASE, and Cochrane Library databases from January 2000 to February 2023, to identify studies investigating the prevalence of cervical hrHPV in KTRs. Pooled cervical hrHPV prevalences, odds ratios (ORs) comparing KTRs to controls and corresponding confidence intervals (CIs) were estimated using random effects logistic regression models. Heterogeneity between studies was assessed through the I2 statistic, and the significance was evaluated by the Cochrane's Q test. Results: Altogether, 16 studies covering >1200 KTRs were included. The prevalence of cervical hrHPV in KTRs was 27.7% (95% CI 21.3–35.1) with substantial interstudy heterogeneity. Stratification indicated a higher prevalence in recent years (2019–2023) and in Asia (39% (95% CI 11.2–61.4)). The prevalence of HPV16 and HPV18 in KTRs was 8.0% (95% CI 3.9–15.9) and 1.7% (95% CI 0.8–3.7), respectively. Comparing hrHPV prevalence in KTRs and controls based on six studies including >500 KTRs and 1000 controls, the OR for hrHPV was 2.0 (95% CI 1.1–3.6). Conclusions: This meta-analysis establishes an increased cervical hrHPV prevalence in KTRs compared to controls. The increased risk may be associated with immunosuppressive therapy post-transplantation. Further research is needed to explore the potential benefits of HPV vaccination, including potential revaccination strategies in KTRs.
AB - Objective: This systematic review and meta-analysis aims to investigate the prevalence of cervical high-risk human papillomavirus (hrHPV) among kidney transplant recipients (KTRs) and, furthermore to compare it to that in immunocompetent controls. Methods: A systematic literature search was conducted in PubMed, EMBASE, and Cochrane Library databases from January 2000 to February 2023, to identify studies investigating the prevalence of cervical hrHPV in KTRs. Pooled cervical hrHPV prevalences, odds ratios (ORs) comparing KTRs to controls and corresponding confidence intervals (CIs) were estimated using random effects logistic regression models. Heterogeneity between studies was assessed through the I2 statistic, and the significance was evaluated by the Cochrane's Q test. Results: Altogether, 16 studies covering >1200 KTRs were included. The prevalence of cervical hrHPV in KTRs was 27.7% (95% CI 21.3–35.1) with substantial interstudy heterogeneity. Stratification indicated a higher prevalence in recent years (2019–2023) and in Asia (39% (95% CI 11.2–61.4)). The prevalence of HPV16 and HPV18 in KTRs was 8.0% (95% CI 3.9–15.9) and 1.7% (95% CI 0.8–3.7), respectively. Comparing hrHPV prevalence in KTRs and controls based on six studies including >500 KTRs and 1000 controls, the OR for hrHPV was 2.0 (95% CI 1.1–3.6). Conclusions: This meta-analysis establishes an increased cervical hrHPV prevalence in KTRs compared to controls. The increased risk may be associated with immunosuppressive therapy post-transplantation. Further research is needed to explore the potential benefits of HPV vaccination, including potential revaccination strategies in KTRs.
KW - Cervix
KW - Genotypes
KW - High-risk human papillomavirus
KW - Human papillomavirus
KW - Kidney transplant recipients
KW - meta-analysis
U2 - 10.1016/j.ypmed.2024.107927
DO - 10.1016/j.ypmed.2024.107927
M3 - Review
C2 - 38467195
AN - SCOPUS:85188090874
VL - 182
JO - Preventive Medicine
JF - Preventive Medicine
SN - 0091-7435
M1 - 107927
ER -
ID: 386414694